PACB
Pacific Biosciences·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 2
Ample Liquidity
EPS Beats Expectation
Dark Cloud Cover
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PACB
Pacific Biosciences Of California, Inc.
A premier life science technology company that develops an integrated platform which records single molecule events in real time for genetic analysis
1305 O’Brien Drive, Menlo Park, California 94025
--
Pacific Biosciences of California, Inc. Founded in Delaware in 2000. The company is a leading life science technology company that is designing, developing and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately solve complex genetic problems. The company's products and technologies under development are derived from two highly differentiated core technologies, focusing on accuracy, quality and completeness, including the existing HiFi long-read sequencing technology and the emerging Sequencing by Binding short-read sequencing technology. The company's products cover a wide range of solutions for a wide range of applications, including human genome sequencing, plant and animal science, infectious disease and microbiology, oncology and other emerging applications.
Earnings Call
Q1/2025
Estimate EPS-0.19
Actual EPS-0.15
Estimate Revenue36.90M
Actual Revenue37.20M
Pacific Biosciences Q1 2025: Navigating Contradictions in Revio Demand, Vega Production, and Financial Outlook
May 19,2025 06:55
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
PACB has released its 2025 Q3 earnings. EPS was reported at -0.12, versus the expected -0.14, beating expectations. The chart below visualizes how PACB has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
PACB has released its 2025 Q3 earnings report, with revenue of 38.44M, reflecting a YoY change of -3.82%, and net profit of -38.00M, showing a YoY change of 37.42%. The Sankey diagram below clearly presents PACB's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
